BioNTech Shares Are Trading Higher After the Company Announced the FDA Allowed Its Partnered Phase 1 Trial for BNT326/YL202 to Resume.
BioNTech Shares Are Trading Higher After the Company Announced the FDA Allowed Its Partnered Phase 1 Trial for BNT326/YL202 to Resume.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.